The aim of this review is to report on the current status of prostate-specific membrane
antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68 Ga …

Prostate cancer is the most common malignant disease in men. Several therapeutic agents
have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) …

Purpose To investigate the improvement of prognostication of active bone metastatic burden
by discriminating bone metastases from degenerative changes in hot foci, using skeletal …

Bone metastasis develops in multiple malignancies with a wide range of incidence. The
presence of multiple bone metastases, leading to a multitude of complications and poorer …

The present article highlights the important progress made in the last two decades in the
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …

Purpose The aims of this study were to calculate bone lesion absorbed doses resulting from
a weight-based administration of 223 Ra-dichloride, to assess the relationship between …

The use of α-emitting radionuclides in targeted alpha therapy (TAT) holds great potential for
treatment of human diseases, such as cancer, due to the short pathlength and high potency …

We retrospectively evaluated the utility of 68Ga-PSMA-11 PET for planning 223RaCl2
therapy of patients with metastatic prostate cancer and its impact on the therapeutic …

Bone metastases are a painful and complex condition that overwhelmingly impacts the
prognosis and quality of life of cancer patients. Over the years, nuclear medicine has made …

α-Particle irradiation of cancerous tissue is increasingly recognized as a potent therapeutic
option. We briefly review the physics, radiobiology, and dosimetry of α-particle emitters, as …